CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.
Also called NCT04369664
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 151 participants
- Sponsor
- Registry
-
NCT04369664
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04369664. Non-randomized; no masking; primary purpose treatment. Start 2020-08-12 (actual); primary completion 2023-09-25 (actual). Results posted on 2024-10-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
- Acronym
- CHORD
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Statin
- Intervention (Drug)
- PCSK9 inhibitor
- Intervention (Drug)
- Ezetimibe 10mg
- Lead sponsor
- NYU Langone Health
Record details
- Record id
cardio:ct-nct04369664- Content hash
5b581c1cc8aac8d38453dbcb2ac8d49b93cfb102ca0fed49611be748422001f4